Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Other Non-Current Assets (2016 - 2025)

Anaptysbio filings provide 10 years of Other Non-Current Assets readings, the most recent being $256000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $256000.0, compared with a TTM value of $256000.0 through Dec 2025, changed 0.0%, and an annual FY2025 reading of $256000.0, changed 0.0% over the prior year.
  • Other Non-Current Assets hit $256000.0 in Q4 2025 for Anaptysbio, roughly flat from $256000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $477000.0 in Q1 2021, with the low at $256000.0 in Q4 2021.
  • Median Other Non-Current Assets over the past 5 years was $256000.0 (2021), compared with a mean of $268277.8.
  • The sharpest move saw Other Non-Current Assets skyrocketed 695.0% in 2021, then crashed 46.33% in 2022.
  • Year by year, Other Non-Current Assets stood at $256000.0 in 2021, then changed by 0.0% to $256000.0 in 2022, then changed by 0.0% to $256000.0 in 2023, then changed by 0.0% to $256000.0 in 2024, then changed by 0.0% to $256000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $256000.0, $256000.0, and $256000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.